You can buy or sell PTI and other stocks, options, ETFs, and crypto commission-free!
Proteostasis Therapeutics, Inc. Common Stock, also called Proteostasis Therapeutics, is a clinical stage biopharmaceutical company, which engages in the discovery and development of novel therapeutics to treat cystic fibrosis (CF), and other diseases caused by an imbalance in the proteostasis network. Read More The company was founded by William Balch, Jeffery W. Kelly, Andrew Dillin, Richard I. Morimoto, Alfred Lewis Goldberg, Daniel Finley, Christopher T. Walsh, and Randall W. King in 2006 and is headquartered in Boston, MA.
52 Week High
52 Week Low
Simply Wall StMar 12
Are Insiders Buying Proteostasis Therapeutics, Inc. (NASDAQ:PTI) Stock?
We’ve lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. The flip side of that is that there are more than a few examples of insiders dumping stock prior to a period of weak performance. So shareholders might well want to know whether insiders have been buying or selling shares in Proteostasis Therapeutics, Inc. (NASDAQ:PTI). What Is Insider Buying? It is perfectly legal for company insiders, including board members, to buy and sell stock in a comp...
Stock Price, News, & Analysis for Proteostasis Therapeutics
Proteostasis Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers and develops novel therapeutics to treat cystic fibrosis and other diseases caused by an imbalance in the proteostasis network. Its lead product candidate is PTI-428, an orally bioavailable cystic fibrosis transmembrane conductance regulator modulator belonging to the amplifier class, which is in Phase II study. The company is also involved in developing PTI-801, a corrector molecule; and PTI-808, a potentiator molecule t...
Guru FocusFeb 25
Detailed Research: Economic Perspectives on Novartis AG, Proteostasis Therapeutics, Williams-Sonoma, Magna International, YRC Worldwide, and Delek Logistics Partners — What Drives Growth in Today's Co
NEW YORK, Feb. 25, 2019 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Novartis AG (:NVS), Proteostasis Therapeutics, Inc. (NASDAQ:PTI), Williams-Sonoma, Inc. (:WSM), Magna International Inc. (:MGA), YRC Worldwide, Inc. (NASDAQ:YRCW), and Delek Logistics Partners, L.P. (:DKL), including updated fundamental summaries, consolidated fiscal reporting, and fully-qu...
-$0.37 per share
Expected Mar 25, After Hours